Search

To study the effect of Xiaoer Xiaoji Zhike Oral Liquid combined with budesonide on serum interferon-γ (IFN-γ), interleukin-4 (IL-4), transforming growth factor β1 (TGF-β1), nitric oxide (NO) level in children with bronchial asthma. Selected 67 cases of patients with bronchial asthma who were treated in our hospital from January 2018 to December 2019, divided into two groups randomly. The control group was treated with budesonide alone, and the observation group was treated with Xiaoer Xiaoji Zhike Oral Liquid combined with budesonide. The effective rate of the observation group 93.94 % was significantly higher than that of the control group 70.59 % (P<0.05). The disappearance time of wheezing, cough disappearance, hospital stay and wheezing disappearance time of the observation group were significantly shorter than control group (P<0.05). After treatment, the levels of serum NO and IL-4 of the two groups of children were significantly reduced (P<0.05), and the levels of serum TGF-β1 and IFN-γ were significantly increased (P<0.05), and the levels of serum NO and IL-4 in the observation group The level of IL-4 was significantly lower than that of the control group (P<0.05), and the levels of serum TGF-β1 and IFN-γ were significantly higher than that of the control group (P<0.05). After treatment, the serum IgM, IgA and IgG levels of the two groups of children were significantly reduced (P<0.05), and the serum IgM, IgA and IgG levels of the observation group were significantly lower (P<0.05). Erxiaoji Zhike Oral Liquid combined with budesonide has a significant effect on children with bronchial asthma. The mechanism may be related to the regulation of serum IFN-γ, IL-4, TGF-β1 and NO levels. [ABSTRACT FROM AUTHOR]

Objective: To investigate the effects of inhalation of recombinant human interferon α-2b combined with budesonide on inflammatory factors and rehabilitation process in children with bronchiolitis. Methods: 102 children with bronchiolitis who were admitted to Huaian Hospital Affiliated to Xuzhou Medical University from March 2015 to May 2018 were selected as the research subjects. According to the digital table method, the children were randomly divided into control group (n=51) and research group (n=51). The control group was given budesonide aerosol inhalation therapy, the research group was treated with recombinant human interferon α-2b on the basis of the control group. The clinical efficacy and clinical indicators of the two groups were compared. The inflammatory factors before and 6d after treatment were compared between the two groups, and adverse reactions of the two groups were observed. Results: The total effective rate in the research group was 92.16% at 6d after treatment, which was significantly higher than that in the control group 76.47% (P<0.05). The time of wheezing disappearance, fever abatement, lung rale disappearance, cough disappearance and hospitalization in the research group were shorter than those in the control group (P<0.05). 6d after treatment, the levels of interleukin-4 (IL-4), interleukin-6 (IL-6) and tumor necrosis factor-α(TNF-α) in both groups were lower than those before treatment, and the research group was lower than the control group (P<0.05). The levels of interferon-γ(INF-γ) were higher than those before treatment, and the research group was higher than the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusions: Recombinant human interferon α-2b combined with budesonide aerosol inhalation in the treatment of children with bronchiolitis has a significant effect,it can effectively improve the clinical symptoms of children, accelerate the rehabilitation process, and can effectively improve the level of inflammatory factors, without increasing the incidence of adverse reactions, it has a certain clinical value. [ABSTRACT FROM AUTHOR]